Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits
Ken Shinmura, MD, PhD*,
Eitaro Kodani, MD*,
Y. u-Ting Xuan, PhD*,
Buddhadeb Dawn, MD*,
Xian-Liang Tang, MD* and
Roberto Bolli, MD, FACC*,*
* Experimental Research Laboratory, Division of Cardiology, University of Louisville, and the Jewish Hospital Heart and Lung Institute, Louisville, Kentucky, USA
View larger version (57K):
[in a new window]
|
Figure 1 Experimental protocols (protocol I): effect of acetylsalicylic acid (aspirin [ASA]) on late preconditioning (PC) against myocardial stunning. O = occlusion; R = reperfusion.
|
|
View larger version (46K):
[in a new window]
|
Figure 2 Experimental protocols (protocols II and III): effect of acetylsalicylic acid (aspirin [ASA]) on platelet function. COX = cyclooxygenase; O = occlusion; R = reperfusion.
|
|
View larger version (28K):
[in a new window]
|
Figure 3 Systolic thickening fraction in group I (control). Illustrated is thickening fraction at baseline, just before the first occlusion (Pre-O), 3 min into each coronary occlusion (O), 3 min into each reperfusion (R), and at selected times during the 5-h reperfusion period after the sixth occlusion. Thickening fraction is expressed as a percentage of baseline values. The two comparisons performed at each time-point from 5 min to 4 h of reperfusion were adjusted with the Bonferroni correction. Data are means ± SEM.
|
|
View larger version (35K):
[in a new window]
|
Figure 4 Total deficit of systolic wall thickening after the sixth reperfusion. The total deficit of systolic wall thickening was measured in arbitrary units, as described in the text. The two comparisons performed in each group were adjusted by the Bonferroni correction. Data are means ± SEM. ASA = acetylsalicylic acid.
|
|
View larger version (31K):
[in a new window]
|
Figure 5 Systolic thickening fraction in group II (low acetylsalicylic acid [aspirin {ASA}] on day 2) (A) and in group III (high ASA on day 1) (B). Same format as Figure 3. In both groups II and III, the two comparisons performed at each time-point from 5 min to 4 h of reperfusion were adjusted with the Bonferroni correction. Data are means ± SEM. Pre-O = before first occlusion; O/R = occlusion/reperfusion.
|
|
View larger version (33K):
[in a new window]
|
Figure 6 Systolic thickening fraction in group IV (high acetylsalicylic acid [aspirin {ASA}] on day 2) (A) and in group V (multiple ASA) (B). Same format as Figure 3. In both groups IV and V, the two comparisons performed at each time-point from 5 min to 4 h of reperfusion were adjusted with the Bonferroni correction. Data are means ± SEM. Pre-O = before first occlusion; O/R = occlusion/reperfusion.
|
|
View larger version (30K):
[in a new window]
|
Figure 7 (Upper panel) Representative Western immunoblots showing the expression of cyclooxygenase (COX-2) protein in the membranous fraction in the ischemic/reperfused region. (Lower panels) Densitometic analysis of COX-2 protein signals in the membranous fraction in the ischemic/reperfused region (anterior left ventricular [LV] wall) (left) and in the nonischemic region (posterior LV wall) (right). In all samples, the densitometric measurements of COX-2 immunoreactivity were expressed as a percentage of the average value measured in the corresponding LV wall of control rabbits. The two comparisons performed in each panel were adjusted by the Bonferroni correction. Data are means ± SEM. ASA = acetylsalicylic acid (aspirin); PC = preconditioning.
|
|
View larger version (30K):
[in a new window]
|
Figure 8 Myocardial levels of prostaglandin (PG)E2 and 6-keto-PGF1 (measured by enzyme immunoassay). The three intergroup comparisons performed in each panel were adjusted by the Bonferroni correction. Data are means ± SEM. ASA = acetylsalicylic acid (aspirin); PC = preconditioning.
|
|
|
